Insulin Resistance Indices and Coronary Artery Disease

NCT ID: NCT06237244

Last Updated: 2024-02-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1017 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-12-01

Study Completion Date

2023-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this retrospective study from professor Kojuri clinic registry, total number of 1017 patients with first angiography were included and all data were recorded from registry. Insulin resistance was calculated using laboratory data

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This was an analytical cross-sectional retrospective study involving patients with suspected CAD who underwent coronary angiography between December 2018 and May 2023. The information was obtained from patients referred to the outpatient cardiovascular clinic (Professor Kojuri Cardiology Clinic, Shiraz, Iran, www.kojuriclinic.com). Data was extracted from Professor Kojuri Cardiology Clinic database, including patient's information about the clinical history, presence or absence of specific diseases, angiography/angioplasty results, medications, and laboratory values.

A total of 14,708 patients who had undergone coronary angiography at least once were examined. After applying exclusion criteria, 1017 eligible cases were selected for data analysis.

The following data was recorded for the included patients: demographic data, past medical history (such as DM, hypertension, etc.), systolic and diastolic blood pressure, weight and height, fasting plasma glucose (FPG), hemoglobin A1c (HbA1c), total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and serum creatinine (Cr). Body mass index (BMI) was calculated as weight (Kg) divided by the square of height (m2). Obesity was defined as BMI ≥ 30 Kg/m2.

Laboratory values were selected from the time before angiography, and if not available, from the time shortly after the angiography. This helped us find those values which could best represent the metabolic state of patients at the time of angiography, while reducing the confounding effect of statin use.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Insulin Resistance Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

coronary artery disease

patients with coronary angiography of at least one vessel with more than 50% stenosis

triglyceride to glucose ratio

Intervention Type DIAGNOSTIC_TEST

Ratio of triglyceride level to glucose

triglycerdie to HDL ratio

Intervention Type DIAGNOSTIC_TEST

Ratio of triglyceride to HDL cholesterol

no coronary artery disease

patient with no stenosis in coronary angiography

triglyceride to glucose ratio

Intervention Type DIAGNOSTIC_TEST

Ratio of triglyceride level to glucose

triglycerdie to HDL ratio

Intervention Type DIAGNOSTIC_TEST

Ratio of triglyceride to HDL cholesterol

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

triglyceride to glucose ratio

Ratio of triglyceride level to glucose

Intervention Type DIAGNOSTIC_TEST

triglycerdie to HDL ratio

Ratio of triglyceride to HDL cholesterol

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with age more than 18 years and having undergone coronary angiography

Exclusion Criteria

* incomplete data
* history of prior coronary angiography or revascularization (percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG))
* serum creatinine \> 1.4 mg/dL
* history of chronic kidney disease (CKD)
* cancer,
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shiraz University of Medical Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Javad Kojuri

professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Javad Kojuri, MD. MS.

Role: PRINCIPAL_INVESTIGATOR

Professor kojuri cardiology clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Shiraz University of Medical Sciences

Shiraz, Fars, Iran

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Iran

References

Explore related publications, articles, or registry entries linked to this study.

Jahangiri S, Mosalamiaghili SA, Heydarzadeh R, Yousefzadeh M, Golchin Vafa R, Zarifkar H, Assadian K, Sohrabizadeh S, Zarifkar H, Sadeghi M, Hosseini N, Montaseri M, Hosseini SA, Kojuri J. Predicting the presence and severity of coronary artery disease using surrogate markers of insulin resistance: A cross-sectional study. ARYA Atheroscler. 2025;21(1):44-53. doi: 10.48305/arya.2025.42573.2960.

Reference Type DERIVED
PMID: 40401209 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IR.SUMS.MED.REC.1402.252

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.